• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (5): 853-862.DOI: 10.3969/j.issn.1671-2587.2026.05.025

Previous Articles     Next Articles

Advances in Individual Variability in Platelet ABH Antigen Expression and Its Functional Implications for Transfusion Medicine

CAO Bowei, CHENG Hong, LI Dandan, WANG Zhicheng   

  1. Department of Transfusion Medicine, Huashan Hospital, Fudan University, Shanghai 200040
  • Received:2026-09-02 Revised:2026-09-23 Online:2026-10-20 Published:2026-11-11

Abstract: Platelet ABH antigens are terminal glycan structures carried by membrane glycoproteins and glycosphingolipids. Their expression reflects endogenous glycosylation along the megakaryocyte-platelet axis and adsorption of ABH-active substances from plasma. The GPⅠb-Ⅸ-Ⅴ complex and integrins can carry ABH determinants, with substantial variation among the A1 and A2 subgroups and the high-expresser phenotype (HXP) and low-expresser phenotype (LXP). HXP and LXP are assay-dependent expression phenotypes rather than new ABO subgroups; their classification varies with reagents, flow-cytometry platforms, analytical methods, and thresholds, and no cross-center standard is currently available. Available functional studies suggest that ABO-related glycosylation may affect the binding kinetics between GPⅠb-Ⅸ-Ⅴ and von Willebrand factor (VWF), Furthermore, anti-A/B antibodies have been shown to alter platelet aggregation, spreading, thrombin generation, and mediator release in vitro. However, these findings are currently insufficient to establish a causal relationship with clinical bleeding or thrombosis events. In transfusion practice, major ABO incompatibility concerns post-transfusion platelet recovery and count increments, minor incompatibility can cause rare but severe hemolysis through passively transfused antibodies, and bidirectional incompatibility combines both risks. When inventory permits, ABO-identical platelets may be considered preferentially. Platelets with A2 or LXP phenotype may be valuable in selected major ABO-incompatible settings, but standardized screening and prospective clinical-outcome evidence remain insufficient for routine recommendation.

Key words: ABH antigens, Platelets, ABO blood-group system, Platelet transfusion, Von Willebrand factor

CLC Number: